The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
CFOs are no longer just funders of AI experiments but central architects of its enterprise-wide deployment, navigating a critical shift from promise to production.
A pivotal week for markets unfolds as Amazon, Alphabet, AMD, and Disney headline a packed earnings calendar. With implied volatility spiking, option traders brace for significant moves across sectors.
Three decades after its birth, New York's Silicon Alley has matured into a distinct tech ecosystem, anchored by profitability, cross-industry ties, and resilience through multiple booms and busts.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Kevin Warsh, a leading candidate for Federal Reserve Chair, has historically framed Bitcoin not as a threat but as a crucial policy signal. His past comments labeling it 'the new gold' for younger investors stand in stark contrast to the cryptocurrency's recent 3% decline, highlighting the volatile intersection of regulatory sentiment and digital asset markets.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.
After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.
Africa's used vehicle market is on track to expand at nearly 7% annually, approaching a $200 billion valuation by 2033, as demand for affordable personal transport surges across the continent.
As Pzena Investment Management's latest commentary highlights a challenging quarter for value strategies, one of its holdings, freight giant Knight-Swift, comes into focus. We examine the investment case for KNX amidst shifting economic currents and a market dominated by AI hype.
Pzena Investment Management's latest quarterly commentary reveals its Focused Value Strategy lagged behind the broader value index in Q4 2025, with agricultural sciences firm FMC Corporation highlighted as a key underperformer amid a market dominated by AI and mega-cap stocks.
